Your browser doesn't support javascript.
loading
Patterns of Continuous Glucose Monitor Use in Young Children Throughout the First 18 Months Following Type 1 Diabetes Diagnosis.
Sinisterra, Manuela; Wang, Christine H; Marks, Brynn E; Barber, John; Tully, Carrie; Monaghan, Maureen; Hilliard, Marisa E; Streisand, Randi.
Afiliación
  • Sinisterra M; Children's National Hospital, Washington, District of Columbia, USA.
  • Wang CH; Children's National Hospital, Washington, District of Columbia, USA.
  • Marks BE; Children's National Hospital, Washington, District of Columbia, USA.
  • Barber J; Children's National Hospital, Washington, District of Columbia, USA.
  • Tully C; The George Washington University School of Medicine, Washington, District of Columbia, USA.
  • Monaghan M; Children's National Hospital, Washington, District of Columbia, USA.
  • Hilliard ME; The George Washington University School of Medicine, Washington, District of Columbia, USA.
  • Streisand R; Children's National Hospital, Washington, District of Columbia, USA.
Diabetes Technol Ther ; 23(11): 777-781, 2021 11.
Article en En | MEDLINE | ID: mdl-34252292
Objective: To describe sociodemographic and parent psychosocial characteristics associated with patterns of continuous glucose monitor (CGM) use across the first 18 months post-type 1 diabetes (T1D) diagnosis among young children. Methods: One hundred fifty-seven parent-child dyads enrolled in a behavioral intervention for parents of young children (1-6 years) newly diagnosed with T1D. Parents reported on baseline sociodemographic characteristics and psychosocial functioning; child CGM use was assessed at five time points during the first 18 months post-diagnosis. Results: Most participants (81.8%) used CGM at least once. Four CGM trajectories emerged (always, later/stable, inconsistent, and never). Participants with private insurance were more likely to be in the always, later/stable, or inconsistent groups versus the never group. Youth in the always and later/stable groups had lower mean HbA1c at 18 months than those in the never group. Conclusions: Given the health benefits of CGM, further exploration of barriers to CGM use in families with public health insurance is needed. ClinicalTrials.gov identifier: NCT02527525.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adolescent / Child, preschool / Humans Idioma: En Revista: Diabetes Technol Ther Asunto de la revista: ENDOCRINOLOGIA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adolescent / Child, preschool / Humans Idioma: En Revista: Diabetes Technol Ther Asunto de la revista: ENDOCRINOLOGIA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos